SCHEMBL15034147

SCHEMBL15034147

CC(C)(C)c1cccc(C(=O)N2CCN(C(=O)c3ncn(-c4ccccc4)n3)C(C)(C)C2)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 3/20 0.41
CFTR P13569 1/20 0.39
MAPT P10636 6/20 0.38
LMNA P02545 3/20 0.38
USP2 O75604 2/20 0.38
TSHR P16473 1/20 0.38
MAPK1 P28482 1/20 0.38
SMN1; SMN2 Q16637 4/20 0.37
TP53 P04637 3/20 0.37
ABL1 P00519 2/20 0.36
BCR P11274 2/20 0.36
POLB P06746 3/20 0.35
HSD17B10 Q99714 1/20 0.35
TDP1 Q9NUW8 1/20 0.34
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
ALDH1A1 P00352 4/20 0.34
HTT P42858 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP3A4 P08684 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15034119 0.92 POLB (0.44) HPGDLMNAUSP2SMN1; SMN2ABL1
SCHEMBL15034134 0.88 CFTR (0.44) HPGDCFTRMAPTTSHRSMN1; SMN2
SCHEMBL15034138 0.88 HPGD (0.44) HPGDCFTRMAPTLMNAUSP2
SCHEMBL15034131 0.87 CYP3A4 (0.48) HPGDUSP2TSHRMAPK1SMN1; SMN2
SCHEMBL15020006 0.87 ALDH1A1 (0.44) HPGDMAPTSMN1; SMN2TP53POLB
SCHEMBL15034149 0.86 SMN1; SMN2 (0.41) CFTRMAPTLMNAUSP2TSHR
SCHEMBL15020047 0.85 HPGD (0.41) HPGDCFTRMAPTLMNAUSP2
SCHEMBL15034139 0.85 ALDH1A1 (0.47) HPGDCFTRMAPTSMN1; SMN2TP53
SCHEMBL15034152 0.85 MAPT (0.39) HPGDCFTRMAPTLMNAUSP2
SCHEMBL15034153 0.85 ALDH1A1 (0.39) HPGDCFTRMAPTLMNAUSP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8883789-B2 Piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-11-11 US disclosed
US-8883789-B2 Piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-11-11 US disclosed
US-20130158042-A1 NOVEL COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-06-20 US disclosed
US-20130158042-A1 NOVEL COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-06-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130158042-A1 NOVEL COMPOUNDS GRM5, GRIK5, GRM1 HPGD 2696/4885CFTR 3753/4885MAPT 270/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.